Genç Kadınlarda İnvaziv Meme Kanseri Histopatolojik Özellikleri ve Hormon Reseptörleri

Öz

Giriş/Amaç:Meme kanseri, özellikle ileri yaş kadınlarda yaygındır. Genç kadınlarda da kansere bağlı ölümlerin önde gelen nedenleri arasındadır. Genç kadınlarda survey daha kısa olup, medikal tedaviye cevap daha düşük olmaktadır, nedeni bu hasta grubunda görülen kanser olgularının diğer yaş gruplarında görülenlerden farklı olarak kanser hücrelerindeki hormon reseptörlerindeki farklılıklar olarak düşünülmektedir. Çalışmamızdaki amaç 40 yaş altı kadınlardaki meme kanserinin klinik, histopatolojik özellikleri, ve hormon reseptörleri değerlendirip, bu yaştaki hastalara uygulanacak medikal tedavilerde farklı yöntemler geliştirilmesi için veri setleri oluşturmaktır. Gereç ve Yöntemler:Hastanemiz patoloji kliniğinde tanı almış 40 yaş altı 72 invaziv meme karsinom vakası; lokalizasyon, tümör büyüklüğü, histolojik grade, lenf nodu tutulumu, multifokalite/multisentrisite, uzak organ metastazı, hormon reseptör (Östrojen-ER, progesteron-PR) durumu, HER2 ve ki-67 proliferasyon belirteçleri retrospektif olarak incelendi. Bulgular:Hastaların yaş ortalaması 35.31 olup, %59.7?si sağ memede lokalizedir. Duktal karsinoma en yaygın histolojik tip olup, olguların %52.8?inde yüksek grade saptandı. Vakaların büyük çoğunluğu ER (%87.5) ve PR (%73.6) pozitif, HER2 (%83.3) negatif bulundu. Ki-67 proliferasyon indeksi %52.8?inde yüksek oranda izlendi. Sonuç:Bu bulgularla genç kadınlarda izlenen meme kanseri tümörlerinin daha yüksek histolojik grade ve yüksek proliferasyon indeksine sahip olduğunu göstermektedir. Bu nedenle bu yaş grubunda görülen kanserlerin biyolojik olarak daha agresif seyredeceğini ve prognozun kötü olacağını göstermektedir.

Anahtar Kelimeler

• Meme Kanseri
• Genç Kadın
• Histopatolojik Özellikleri
• Hormon Reseptörleri

Invasıve Breast Cancer Histopathological Properties and Hormone Receptors In Young Women

Abstract

Objective:Breast cancer is common, especially in older women. It is also one of the leading causes of cancer-related deaths in young women. Survey in young women is shorter and the response to medical treatment is lower, because cancer cases in this group of patients are considered as differences in hormone receptors in cancer cells, unlike those seen in other age groups. The aim of our study is to evaluate the clinical, histopathological features, and hormone receptors of breast cancer in women under the age of 40, and to create datasets to develop different methods in medical treatments to be applied to patients of this age. Methods:Localization, tumor size, histological grade, lymph node involvement, multifocality/multicentricity, distant organ metastasis, hormone receptor (Estrogen-ER, progesterone-PR) status, HER2 and ki-67 proliferation markers were retrospectively analyzed in 72 invasive breast carcinoma cases under the age of 40 diagnosed in the pathology clinic of our hospital. Results:The average age of the patients is 35.31 and 59.7 % of them are localized in the right breast. Ductal carcinoma is the most common histological type, and high grade was detected in 52.8 % of cases. The majority of cases were ER (87.5%) and PR (73.6 %) positive, HER2 (83.3 %) negative. Ki-67 proliferation index was observed at a high rate in 52.8 %. Conclusion:These findings show that breast cancer tumors observed in young women have higher histological grade and high proliferation index. Therefore, it shows that cancers seen in this age group will progress more biologically and the prognosis will be poor.

Keywords

• Breast Cancer
• Histopathological Features
• Hormone Receptors
• Young Woman

References

1. 1- Mehrabi E, Hajian S, Simbar M, Hoshyari M, Zayeri F. Coping response following a diagnosis of breast cancer: A systematic review. Electronic physician 2015; 7(8): 1575.
2. 2- Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS. Epidemiology and prognosis of breast cancer in young women. J ThoracDis 2013; 5(1): S2-8. 3- Reyna C, Lee MC. Breastcancer in young women: special considerations in multidisciplinary care. Journal of multidisciplinary healthcare 2014; 7: 419-29.
3. 4- Chung M, Chang HR, Bland KI, Wanebo HJ. Younger women with breast carcinoma have poorer prognosth an older women. Cancer 1996; 77: 97-103.
4. 5- Gajdos C, Tarrter PI, Bleiweiss IJ, Bodian C, Brower ST. Stage 0 tostage III breast cancer in young women. J AmColl Surg 2000; 190: 523-9.
5. 6- Azim HA, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res 2014; 16: 427.
6. 7- Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment. PLoSOne 2009; 4:e7695.
7. 8- Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Veronesi P, Torrisi R, Montagna E, Luini A, Intra M, Gentilini O, Ghisini R, Goldhirsch A, Colleoni M. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. AnnOncol 2010; 21: 1974–1981.
8. 9- Han W, Kang SY. Relationship between age at diagnosis and outcome of premenopausal breast cancer: ageless than 35 years is a reason ablecut-off for defining young age-onset breast cancer. Breast Cancer Res Treat 2010; 119:193–200.

9. 10- Azim HA Jr, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, Haibe-Kains B, Piccart MJ, Sotiriou C, Loi S. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res 2012; 18:1341–1351.
10. 11- Maughan KL, Lutterbie MA, Ham PS. Treatment of breast cancer. Am Fam Physician 2010; 81(11): 1339-46.
11. 12- Januškevičienė I, PetrikaitėV. Heterogeneity of breast cancer: the importance of interaction between different tumor cell populations. Life Sci 2019 Oct 24;239:117009. 13- Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19: 403–10
12. 14- Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206-23.
13. 15- Ali A, Fergus K, Wright FC, Pritchard KI, Kiss A, Warner E. The impact of a breast cancer diagnosis in young women on their relationship with their mothers. Breast. 2014; 23: 50-5.
14. 16- Chen HL, Zhou MQ, Tian W, Meng KX, He HF. Effect of age on breast cancer patient prognoses: a population-based study using the SEER 18 database. PLoS One 2016; 11(10): e0165409.
15. 17- Copson E, Eccles B, Maishman T, Gerty S, Stanton L, Cutress RI, Altman DG, Durcan L, Simmonds P, Lawrence G, Jones L, Bliss J, Eccles D. POSH Study Steering Group: Prospective observational study of breast cancer treatment outcomes for UK women aged 18–40 years at diagnosis: the POSH study. J Natl Cancer Inst 2013; 105: 978–988.
16. 18- Grignol VP, Agnese DM. Breast Cancer Genetics for the Surgeon: An Update on Causes and Testing Options. Journal of the American College of Surgeons 2016; 222(5): 906-914.
17. 19- Newman B, Austin MA, Lee M, King MC. Inheritance of human breast cancer: evidence for autosomal dominant transmission in highrisk families. Proceedings of the National Academy of Sciences 1988; 85(9): 3044-3048.
18. 20- Reza YC, Hajian-Tilaki K, Sharbatdaran M. Comparison of pathologic characteristics of breast cancer in younger and older women. Caspian J InternMed 2019; 10(1): 42–47.
19. 21- Henouda S, Bensalem A, Rouabah L. Breast Carcinoma in Younger Algerian Eastern Women: Epidemiological Profile in Series of 135 Cases. ScienceResearch 2015; 3(4): 198-205
20. 22- Hariharan N, Rao TS, Naidu CK, Raju KVVN, Rajappa S, Ayyagari S, Krishnamohan MVT, Murthy S, Suryadevara A, Boleneni N. The Impact of Stage and Molecular Subtypes on Survival Outcomes in Young Women with Breast Cancer. J Adolesc Young Adult Oncol 2019; 8(5): 628-634.
21. 23- Erić I, Petek Erić A, Kristek J, Koprivčić I, Babić M. Breast cancer in young women: pathologic and immunohistochemical features. Acta Clin Croat 2018; 57(3): 497-502.
22. 24- Agrup M, Stal O, Olsen K, Wingren S. C-erbB-2 overexpression and survival in early onset breast cancer. Breast Cancer Res Treat 2000; 63(1): 23-9.
23. 25- Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC. Adolescents and Young Adults with Breast Cancer have More Aggressive Disease and Treatment Than Patients in Their Forties. Ann Surg Oncol 2019; 26(12): 3920-3930.
24. 26- Yoshioka T, Hosoda M, Yamamoto M, Taguchi K, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y, Yamashita H. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Breast Cancer 2015; 22(2): 185-91.